PMID- 33718158 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220421 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 11 DP - 2021 TI - Evaluation of Risk Factors for Laryngeal Squamous Cell Carcinoma: A Single-Center Retrospective Study. PG - 606010 LID - 10.3389/fonc.2021.606010 [doi] LID - 606010 AB - BACKGROUND: The survival rate of patients with laryngeal squamous cell carcinoma (LSCC) is correlated with several factors. However, the independent prognostic factors of patients with LSCC remain unclear. Thus, we sought to identify prognostic factors affecting LSCC outcomes in the Chinese population. METHODS: The survival and potential prognostic factors of 211 patients with LSCC between April 2011 and July 2019 were retrospectively analyzed. Overall survival (OS) and progression free survival (PFS) were estimated by the Kaplan Meier method, and a log-rank test was used to compare the possible prognostic factors between different groups. The Cox proportional hazard model was used to perform multivariable analysis of significant covariants. RESULTS: A total of 211 LSCC patients were included, of which 164 (77.7%) were male and 47 (22.3%) were female. Mean age was 62.19 +/- 8.328 years. A univariate analysis showed that seven factors including pathological differentiation, clinical stage, tobacco consumption, alcohol consumption, T stage, N stage, and concurrent chemoradiotherapy were correlated with survival (P<0.05). Cox proportional hazards regression analyses revealed that clinic stage (hazard ratio=3.100, p=0.048), pathological differentiation (hazard ratio = 2.538, p=0.015), alcohol consumption (hazard ratio = 8.456, p =0.004) were associated with OS in LSCC. Pathological differentiation (hazard ratio =5.677, p=0.000), alcohol consumption (hazard ratio =6.766, p=0.000) were associated with PFS in LSCC. CONCLUSIONS: Pathological differentiation, alcohol consumption, are independent prognostic factors and predictors of recurrence in LSCC. These factors could help inform guidelines for clinical treatment and prognosis. CI - Copyright (c) 2021 Zhang, Wang, Zhao, Zhang, Zheng, Liu, Liu, Meng, Xin and Jiang. FAU - Zhang, Qihe AU - Zhang Q AD - Department of Radiation Oncology, The First Hospital of Jilin University, Changchun, China. AD - Jilin Provincial Key Laboratory of Radiation Oncology & Therapy, The First Hospital of Jilin University, Changchun, China. AD - NHC Key Laboratory of Radiobiology, School of Public Health, Jilin University, Changchun, China. AD - Key Laboratory of Pathobiology, Ministry of Education, Jilin University, Changchun, China. FAU - Wang, Huanhuan AU - Wang H AD - Department of Radiation Oncology, The First Hospital of Jilin University, Changchun, China. AD - Jilin Provincial Key Laboratory of Radiation Oncology & Therapy, The First Hospital of Jilin University, Changchun, China. AD - NHC Key Laboratory of Radiobiology, School of Public Health, Jilin University, Changchun, China. FAU - Zhao, Qin AU - Zhao Q AD - Department of Radiation Oncology, The First Hospital of Jilin University, Changchun, China. AD - Jilin Provincial Key Laboratory of Radiation Oncology & Therapy, The First Hospital of Jilin University, Changchun, China. AD - NHC Key Laboratory of Radiobiology, School of Public Health, Jilin University, Changchun, China. FAU - Zhang, Yuyu AU - Zhang Y AD - Department of Radiation Oncology, The First Hospital of Jilin University, Changchun, China. AD - Jilin Provincial Key Laboratory of Radiation Oncology & Therapy, The First Hospital of Jilin University, Changchun, China. AD - NHC Key Laboratory of Radiobiology, School of Public Health, Jilin University, Changchun, China. FAU - Zheng, Zhuangzhuang AU - Zheng Z AD - Department of Radiation Oncology, The First Hospital of Jilin University, Changchun, China. AD - Jilin Provincial Key Laboratory of Radiation Oncology & Therapy, The First Hospital of Jilin University, Changchun, China. AD - NHC Key Laboratory of Radiobiology, School of Public Health, Jilin University, Changchun, China. FAU - Liu, Shiyu AU - Liu S AD - Department of Radiation Oncology, The First Hospital of Jilin University, Changchun, China. AD - Jilin Provincial Key Laboratory of Radiation Oncology & Therapy, The First Hospital of Jilin University, Changchun, China. AD - NHC Key Laboratory of Radiobiology, School of Public Health, Jilin University, Changchun, China. FAU - Liu, Zijing AU - Liu Z AD - Department of Radiation Oncology, The First Hospital of Jilin University, Changchun, China. AD - Jilin Provincial Key Laboratory of Radiation Oncology & Therapy, The First Hospital of Jilin University, Changchun, China. AD - NHC Key Laboratory of Radiobiology, School of Public Health, Jilin University, Changchun, China. FAU - Meng, Lingbin AU - Meng L AD - Department of Hematology and Medical Oncology, Moffitt Cancer Center, Tampa, FL, United States. FAU - Xin, Ying AU - Xin Y AD - Key Laboratory of Pathobiology, Ministry of Education, Jilin University, Changchun, China. FAU - Jiang, Xin AU - Jiang X AD - Department of Radiation Oncology, The First Hospital of Jilin University, Changchun, China. AD - Jilin Provincial Key Laboratory of Radiation Oncology & Therapy, The First Hospital of Jilin University, Changchun, China. AD - NHC Key Laboratory of Radiobiology, School of Public Health, Jilin University, Changchun, China. LA - eng PT - Journal Article DEP - 20210225 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 PMC - PMC7947300 OTO - NOTNLM OT - Chinese population OT - laryngeal squamous cell carcinoma OT - overall survival OT - prognostic factors OT - progression-free survival COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/03/16 06:00 MHDA- 2021/03/16 06:01 PMCR- 2021/01/01 CRDT- 2021/03/15 07:07 PHST- 2020/09/14 00:00 [received] PHST- 2021/01/18 00:00 [accepted] PHST- 2021/03/15 07:07 [entrez] PHST- 2021/03/16 06:00 [pubmed] PHST- 2021/03/16 06:01 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2021.606010 [doi] PST - epublish SO - Front Oncol. 2021 Feb 25;11:606010. doi: 10.3389/fonc.2021.606010. eCollection 2021.